SynthesisSeminars in arthritis and rheumatism2019
Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension.
Synthesis in Seminars in arthritis and rheumatism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review of the incidence, risk factors and prognosis of acute exacerbation of systemic autoimmune disease-associated interstitial lung disease.BMC pulmonary medicine · 2021Pooled it
- Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries.Arthritis & rheumatology (Hoboken, N.J.) · 2021Pooled it
- Mitochondrial Dysregulation and Molecular Signaling in Systemic Sclerosis Cardiac Disease: An Integrative Echocardiographic, Microvascular, and Biomarker Review.International journal of molecular sciences · 2026Review
- Beyond IPF: Pulmonary Function Test Predictors of Echocardiographic Pulmonary Hypertension Across the Spectrum of ILD.Pulmonary circulation · 2026Article
- A Lung Ultrasound-Integrated Clinical Model for Predicting Pulmonary Arterial Hypertension in Patients with Connective Tissue Disease-Associated Interstitial Lung Disease.Diagnostics (Basel, Switzerland) · 2026Article
- [Lung involvement in connective tissue diseases].Zeitschrift fur Rheumatologie · 2025Review
- Myocardial Disease in Systemic Sclerosis: Recent Updates and Clinical Implications.Current cardiology reports · 2025Review
- Definition, classification and diagnosis of pulmonary hypertension.The European respiratory journal · 2024Article
- N-terminal pro-brain natriuretic peptide is associated with pulmonary hypertension or diastolic dysfunction in patients with systemic sclerosis: An Australian prospective cross-sectional study.Journal of scleroderma and related disorders · 2024Article
- Diagnosis and Management of Pulmonary Hypertension: New Insights.Diagnostics (Basel, Switzerland) · 2024Review
- Recent developments in connective tissue disease associated pulmonary arterial hypertension.International journal of cardiology. Congenital heart disease · 2024Review
- Right ventricular dyssynchrony for the prediction of prognosis in patients with systemic lupus erythematosus-aaociated pulmonary arterial hypertension: a study with two-dimensional speckle tracking.The international journal of cardiovascular imaging · 2024Article
- The prognostic value of prognostic nutritional index in postoperative onset of PAH in children with isolated VSD: a prospective cohort study based on propensity score matching analysis.Frontiers in pediatrics · 2024Article
- Retrospective cohort study of pulmonary arterial hypertension associated with connective tissue disease effect on patients' prognosis.Clinical rheumatology · 2023Article
- Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment.Clinical rheumatology · 2023Review
- Long-Term Survival of Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Single-Center Cohort.Acta Cardiologica Sinica · 2023Article
- Clinical characteristics and risk factors for primary SjögrenZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- 2023 Taiwan Society of Cardiology (TSOC) and Taiwan College of Rheumatology (TCR) Joint Consensus on Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.Acta Cardiologica Sinica · 2023Article
- Article
- WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.European respiratory review : an official journal of the European Respiratory Society · 2022Review
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
Abstract
objectivePulmonary arterial hypertension (PAH) has high morbidity and mortality in connective tissue diseases (CTDs), especially systemic sclerosis (SSc). In this systematic review, we provide an update on screening measures for early detection of PAH in CTD.
methodsManuscripts published between July 2012 and October 2017, which incorporated screening measures to identify patients with PAH by right heart catheterization, were identified. Risk of bias was assessed using the QUADAS-2 tool.
resultsThe systematic review resulted in 1514 unique citations and 22 manuscripts were included for final review; the majority of manuscripts had a lower risk of bias based on the QUADAS-2 tool. There were 16 SSc cohort studies and 6 case-control studies (SSc 4, SLE 2). Four SSc cohort studies evaluated transthoracic echocardiography (TTE) only. Eight SSc cohort studies evaluated composite measures including ASIG, DETECT, and a combination of tricuspid regurgitation velocity (TRV) and PFT variables. DETECT and ASIG had greater sensitivity and negative predictive value (NPV) compared to the 2009 ESC/ERS guidelines in different cohorts. The addition of PFT variables, such as DLCO or FVC/ DLCO ratio, to TRV, resulted in greater sensitivity and NPV compared to TRV alone.
conclusionCurrent screening for PAH in CTDs is centered on SSc. Data continues to support the use of TTE and provides additional evidence for use of composite measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.